ARCHIVED - NRC Helps Companies Grow in the National Capital Region

Archived Content

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

February 04, 2004— Ottawa, Ontario

NRC 100 Sussex Drive Laboratories.

NRC's Sussex Laboratories – home to the NRC Steacie Institute for Molecular Sciences (NRC-SIMS), the NRC Institute for Biological Sciences (NRC-IBS), and some NRC executive offices – is also the location of an NRC Industry Partnership Facility (IPF).

NRC Planting Seeds of Innovation Across Canada

NRC is establishing a network of Industry Partnership Facilities (IPFs) at its research institutes across the country to accelerate innovation, commercialization and to foster the growth of technology clusters all across Canada.

By locating at an NRC-IPF, small and medium sized enterprises (SMEs) gain access to world-class research facilities and expertise, national and international networks, as well as business intelligence and knowledge dissemination resources.

NRC IPFs act as magnets; they attract innovative firms to our facilities, expertise and national networks. Many are purposely designed for specific industries. They are the building blocks for technology clusters.

There are currently NRC IPFs located in Montreal (biopharmaceuticals), Ottawa (information and micro-structural technologies, biotechnology/pharmaceutical), Saskatoon (agri-biotechnology), Fredericton (information technology), Longueuil (manufacturing technologies), Vancouver (fuel cells), Victoria (radio and database technologies) and St. John's (ocean technologies). Facilities are under construction in Edmonton (nanotechnology), Winnipeg (medical technologies) and Halifax (life sciences).

Officially opened in April 2003, the 185 square meter facility will help strengthen Ottawa's burgeoning life sciences cluster.

"This IPF is different from other NRC IPFs as it consists solely of offices that are primarily used for the companies' management," explains Lise Hughes, manager of the Sussex IPF. The incubating companies also occupy other offices and laboratories throughout the building."

The IPF has been a great success with 90 per cent of the offices occupied. Six companies are currently incubating at the Sussex IPF: Brookfield Pharma Corp., Liska Biometry, Occell Inc., Painceptor Pharma, PharmaGap Inc., and Sussex Research Laboratories Inc.

Future plans for the IPF include the addition of a generic laboratory.

The Tenants...

  • Liska Biometry Inc. has developed a new technology that improves the accuracy, repeatability and applicability of using biometry for precise, exact, and certain identification of individuals through fingerprints. (
  • Occell Inc. is a pharmaceutical company involved in research and development of new therapeutic products with applications in oncology.
  • PainCeptor Pharma is a development stage pharmaceutical company focused on the treatment of pain. PainCeptor's peripherally acting therapeutics are designed to eliminate both acute and chronic pain without the side effects associated with centrally acting opioid derivatives.
  • PharmaGap's key area of expertise is both R&D in the field of Gap Junction Intercellular Communication to design effective and safe drugs against cancer, multi-drug resistance and neuro-degenerative conditions, as well as supplying industry with 3D cell-based assays and biological evaluation services focusing on ADMET. (
  • Sussex Research Laboratories Inc. develops proprietary carbohydrate-based synthetic technologies for drug and vaccine research, discovery and development. Sussex specializes in the chemical and chemoenzymatic synthesis of highly pure glycoconjugates such as glycoamino acids, glycolipids and glycopeptides. (

Enquiries: Media relations
National Research Council of Canada

Stay connected


Date modified: